

Special Issue

Cholesterol Metabolism in Cancers and Therapeutic Innovations

Message from the Guest Editors

This Special Issue on cholesterol metabolism in cancer and therapeutic innovations will focus on strategies for improving cancer treatment efficacy in vitro or in vivo. Of particular interest will be manuscripts revealing the contribution of cholesterol metabolism dysregulation in oncogenesis. Manuscripts describing the pharmacological characterization of natural or synthetic drug candidates targeting sterol biosynthesis and metabolism directly or indirectly are encouraged. This Special Issue will include original research, review articles, commentaries, and editorials discussing cholesterol metabolism deregulations and targeting in cancers. Topics of interest for this Special Issue include, but are not limited to, the keywords listed below.

- oxysterol, oxyphytosterol, steroidal alkaloids, cholesterol biosynthesis, LDL, HDL, CD36, SRB1, cell proliferation, metastasis, antitumor immune response

Guest Editors

Dr. Marc Poirot

Cholesterol Metabolism and Therapeutic Innovations Team, UMR 1037 INSERM-Toulouse University, Toulouse, France

Dr. Sandrine Silvente-Poirot

Cholesterol Metabolism and Therapeutic Innovations Team, CRCT UMR1037 INSERM, Université de Toulouse, Toulouse, France

Deadline for manuscript submissions

closed (30 December 2018)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/15935

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).